LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Werfen to Acquire Transfusion and Transplant Diagnostics Innovator for Around USD 2 Billion

By LabMedica International staff writers
Posted on 08 Nov 2022
Print article
Image: Werfen will expand its presence in specialized diagnostics with the acquisition of Immucor (Photo courtesy of Werfen)
Image: Werfen will expand its presence in specialized diagnostics with the acquisition of Immucor (Photo courtesy of Werfen)

Werfen (Barcelona, Spain) has agreed to acquire Immucor, Inc. (Norcross, GA, USA), a privately held corporation with a global presence in transfusion and transplant in vitro diagnostics, at a purchase price of approximately USD 2 billion. The acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories. The transaction is expected to close during the first half of 2023, subject to customary regulatory approvals.

"As a global leader in the research, development, manufacturing and distribution of innovative, Specialized Diagnostics solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model," said Marc Rubiralta, President of Werfen. "We highly value Immucor's commitment to enhancing care for all patients in need of a transfusion or transplant. This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen's values."

"I am confident that by combining two complementary, outstanding Specialized Diagnostics companies, Werfen will expand its global presence with greater diversification, while successfully maintaining its focus on specialization," Rubiralta added.

"Immucor's expertise and innovations in transfusion and transplant diagnostics enable us to enter new markets and will help achieve our vision to be the preferred choice of the most advanced laboratory and point-of-care customers, globally," said Carlos Pascual, CEO of Werfen. "It will be a major milestone in the future of Werfen."

"As we look to the future, we are excited to grow our impact as part of Werfen, a company that shares our long-term vision and commitment to advancing patient care globally," said Avi Pelossof, CEO of Immucor. "As the value of diagnostics in the healthcare system grows, we are confident that Immucor will continue to innovate and succeed under Werfen's ownership."

Related Links:
Werfen
Immucor, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more